← Eichor
Condition: Tumor Recurrence And Metastasis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Tumor Recurrence And Metastasis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06413992Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recu
Phase 2 · 1 location(s) · Mayo Clinic · NCT07073794Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
NA · 1 location(s) · Chang Gung Memorial Hospital · NCT06262386A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
Phase N/A · 1 location(s) · Xinhua Zhang, MD · NCT05464875A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combi
Phase 1 · 1 location(s) · PharmaMatrix Holdings Ltd · NCT04823897A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Ca
Phase 3 · 205 location(s) · Merus B.V. · NCT06525220CAIX PET/ CT Guided Radiation Therapy in CcRCC.
NA · 1 location(s) · Peking University First Hospital · NCT07540260A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT07300449Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
NA · 1 location(s) · The University of Hong Kong · NCT06292286A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurr
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07520760A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H
Phase 3 · 1 location(s) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · NCT07533123Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell C
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06006169Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT06616623Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive
NA · 3 location(s) · Fondation Hôpital Saint-Joseph · NCT06061705A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07137494Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognosticat
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT06678724BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Phase 1 · 14 location(s) · Riboscience, LLC. · NCT05270213Colorectal Metastasis Prevention International Trial 2
Phase 2 · 6 location(s) · Assaf-Harofeh Medical Center · NCT03919461A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
Phase 1/Phase 2 · 1 location(s) · BriaCell Therapeutics Corporation · NCT06471673LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT07325539Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07111832PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
NA · 1 location(s) · University of Washington · NCT04151940Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant R
Phase 2 · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT06259721Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
Phase 1/Phase 2 · 1 location(s) · Coordination Pharmaceuticals, Inc. · NCT05838729
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.